scholarly journals Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults)

2018 ◽  
Vol 15 (1) ◽  
pp. 53-70 ◽  
Author(s):  
Ivan I. Dedov ◽  
Galina A. Mel'nichenko ◽  
Marina V. Shestakova ◽  
Ekaterina A. Troshina ◽  
Natalya V. Mazurina ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Morbid Obesity ◽  
Obesity Treatment ◽  
Clinical Recommendations ◽  
Surgical Methods ◽  
Prevalence Of Obesity ◽  
Treatment Of Obesity ◽  
First Time

The presented paper is a third revision of the clinical recommendations for the treatment of morbid obesity in adults. Morbid obesity is a condition with body mass index (BMI) 40 kg / m2 or a BMI 35 kg / m2 in the presence of serious complications associated with obesity. The recommendations provide data on the prevalence of obesity, its etiology and pathogenesis, as well as on associated complications. The necessary methods for laboratory and instrumental diagnosis of obesity are described in detail. In this revision of the recommendations, the staging of prescribing conservative and surgical methods for the treatment of obesity are determined. For the first time, a group of patients with obesity and type 2 diabetes mellitus is selected, in whom metabolic surgery allows a long-term improvement in the control of glycemia or remission of diabetes mellitus.

scholarly journals A REVIEW ARTICLE-GESTATIONAL DIABETES MELLITUS

2016 ◽  
Vol 9 (1) ◽  
pp. 1
Author(s):  
Muhas C. ◽  
Naseef P. P.
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Cesarean Sections ◽  
Present Generation ◽  
To Come ◽  
First Time ◽  
Carbohydrate Intolerance

Diabetes mellitus is a chronic illness that requires continuing medical care and ongoing patient self-management education and support to prevent acute complications and to reduce the long-term complications. Moderate to severe maternal hyperglycemia in pregnancy has unique diabetes-related risks to mother and her unborn baby. So Gestational Diabetes mellitus (GDM) is a carbohydrate intolerance that is not diabetes that has developed or been discovered for the first time during pregnancy. Approximately 7% of pregnancies are affected by GDM. Patient with GDM are at higher risk for excessive weight gain, preeclampsia, and cesarean sections. Infants born to mothers with GDM are at higher risk for macrosomia, birth trauma, and shoulder dystocia. After delivery, these infants have a higher risk of developing hypoglycemia, hypocalcemia, hyperbilirubinemia, respiratory distress syndrome, polycythemia and subsequent obesity and type 2 diabetes. So the management of GDM is very important, and its management remains a challenge for the obstetricians and endocrinologists. MNT is the most common therapy which suffices for GDM, but when required. The pharmacological treatment becomes necessary, and the treatment of choice is human insulin. OHAs have also reached the high tables in the management of GDM. Glyburide and metformin have been found to be safe, effective and economical for the treatment of gestational diabetes. Let us join hands to manage the GDM effectively, not only for the present generation but also for the generations to come.

scholarly journals Medicines for the Treatment of Obesity

2021 ◽  
Vol 22 (8) ◽  
pp. 3866
Author(s):  
Soon Shik Shin ◽  
Michung Yoon
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Disorders ◽  
Lifestyle Modification ◽  
Caloric Intake ◽  
Morbidly Obese ◽  
Treatment Of Obesity ◽  
The U.S

Obesity is the result of an energy imbalance caused by an increased ratio of caloric intake to energy expenditure. In conjunction with obesity, related metabolic disorders, such as type 2 diabetes mellitus, dyslipidemia and hypertension, have become global health problems [1]. Reducing body weight by lifestyle modification is recommended, but drug intervention is necessary for morbidly obese individuals. Four drug therapies, including orlistat, naltrexone/bupropion, phentermine/topiramate and liraglutide, were approved for long-term use by the U.S. [...]

scholarly journals Clinical treatment of obesity: are drugs and surgery the answer?

2005 ◽  
Vol 64 (1) ◽  
pp. 65-71 ◽  
Author(s):  
Peter G. Kopelman
Keyword(s):  
Obesity Treatment ◽  
Effective Population ◽  
Happy Ending ◽  
Great Expectation ◽  
Prevalence Of Obesity ◽  
Healthy Body Weight ◽  
Treatment Of Obesity ◽  
Major Emphasis ◽  
Sophisticated Technology

Obesity treatment remains a ‘Cinderella’ of all clinical management programmes, but generally without a happy ending. The great expectation for new therapeutic agents has not been fulfilled in clinical practice, whilst the restriction of eating through surgical division of the upper bowel seems strange in an age of advanced and sophisticated technology. The better understanding of the neuro-regulation of appetite, and its application as part of evidence-based clinical interventions, could lead to a more coherent approach to obesity treatment. Nevertheless, investigation of potential neuroendocrine targets for appetite suppression suggests redundancy in the systems, which make development of effective agents against single receptors impractical. Importantly, the progressive rise in the prevalence of obesity will inevitably mean that only a small proportion of afflicted patients will actually be treated by long-term drugs and surgery. Drugs and surgery are not currently the answer for the majority of obese individuals. What is required is a better way of identifying patients who may particularly benefit from such approaches. However, the major emphasis must be the development of effective population-wide interventions that halt the increase in fatness and ensure that future generations maintain and enjoy a healthy body weight.

Obesity, Nutrition, and Physical Activity

2010 ◽  
pp. 127-137
Author(s):  
Donald D. Hensrud
Keyword(s):  
Physical Activity ◽  
Diabetes Mellitus ◽  
Health Benefits ◽  
The United States ◽  
Dietary Factors ◽  
Long Term Results ◽  
Childhood And Adolescence ◽  
Prevalence Of Obesity ◽  
Treatment Of Obesity

The prevalence of obesity has increased markedly over the past few decades in the United States. This increase has occurred across all ethnic groups and all ages, including childhood and adolescence. After obesity has developed, long-term results from the treatment of obesity are generally poor. The importance of diet and nutrition in the prevention of the disease has been widely reported. An estimated 365,000 deaths occur each year because of suboptimal diet and activity habits. Dietary factors play a prominent role in 5 of the 10 leading causes of death for Americans: heart disease, cancer, stroke, diabetes mellitus, and cerebrovascular disease. The health benefits of physical activity and exercise are broad, strong, and well-documented. Health benefits appear to increase linearly with the total amount of physical activity.

Long-Term Efficacy and Safety of Ertugliflozin in Patients (Pts) with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin (MET) Monotherapy—104-Week VERTIS MET Trial

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1129-P
Author(s):  
SILVINA GALLO ◽  
BERNARD CHARBONNEL ◽  
ALLISON GOLDMAN ◽  
HARRY SHI ◽  
SUSAN HUYCK ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Efficacy And Safety ◽  
Term Efficacy

TYPE 2 DIABETES MELLITUS REMISSION AND ITS PREDICTION AFTER TWO-STAGE SURGICAL TREATMENT OF PATIENTS WITH MORBID OBESITY

2019 ◽  
Vol 72 (5) ◽  
pp. 739-743
Author(s):  
Oleksandr Yu. Ioffe ◽  
Mykola S. Kryvopustov ◽  
Yuri A. Dibrova ◽  
Yuri P. Tsiura
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Morbid Obesity ◽  
Weight Loss ◽  
Type 2 Diabetes Mellitus ◽  
Surgical Treatment ◽  
Two Stage ◽  
C Peptide ◽  
Peptide Level

Introduction: Morbid obesity (MO) has a significant impact on mortality, health and quality of life of patients. Type 2 diabetes mellitus (T2DM) is a common comorbidity in patients with MO. The aim is to study T2DM remission and to develop a prediction model for T2DM remission after two-stage surgical treatment of patients with MO. Materials and methods: The study included 97 patients with MO. The mean BMI was 68.08 (95% CI: 66.45 - 69.71) kg/m2. 70 (72,2%) patients with MO were diagnosed with T2DM. The first stage of treatment for the main group (n=60) included the IGB placement, for the control group (n=37) - conservative therapy. In the second stage of treatment the patients underwent bariatric surgery. The study addresses such indicators as BMI, percentage of weight loss, percentage of excess weight loss, ASA physical status class, fasting glucose level, HbA1c, C-peptide. Results: Two-stage treatment of morbidly obese patients with T2DM promotes complete T2DM remission in 68.1% of patients. The risk prediction model for failure to achieve complete T2DM remission 12 months after LRYGB based on a baseline C-peptide level has a high predictive value, AUC = 0.84 (95% CI: 0.69-0.93), OR = 0.23 ( 95% CI: 0.08-0.67). Conclusions: Two-stage treatment of patients with MO promotes improvement of carbohydrate metabolism indicators. With a C-peptide level > 3.7 ng/ml, prediction of complete T2DM remission 12 months after Laparoscopic Roux-en-Y Gastric Bypass is favorable.

Sign in / Sign up

Export Citation Format

Share Document